GERN - geron.com Price to Earnings Adjusted for Growth Rate

Geron Corporation (GERN) is a pioneer in developing telomerase inhibitors with a unique drug portfolio. The change in the PEG ratio reflects the valuation dynamics relative to earnings growth, where 0.00 becomes the new value of the indicator. Growth potential is supported by the commercial success of Rytelo and interest from big pharma, while FDA approval and patent protection create a sustainable market moat.

GERN: geron.com Price/Earnings to Growth Ratio 07/04/2022 - 11/12/2026

Analytical breakdowns for Geron Corporation (GERN)

- market value and analyst target forecast:

Price Rate Chart Geron Corp|GERN - Consensus Target

- market capitalization statistics:

Market Value Geron Corp.|GERN - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Accounting Value of a Share Geron|GERN - Company Book Value|Market Capitalization to Net Assets geron.com|GERN - Aggregate Company Assets

- business debt structure and liquidity details:

- earnings and valuation multiples information:

GERN - Company Net Income|Expected Net Income Geron Corporation|GERN - Price to Earnings Ratio|Projected Price to Earnings Geron Bio|GERN - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Geron Corp.|GERN - Operating profit EBITDA|Net earnings per share for the trailing year Geron|GERN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months geron.com|GERN - Earnings per share growth in current year|Expected earnings per share trend next year Geron Corporation

Summary company analytics:Geron Corp

The PEG ratio compares the P/E ratio with earnings growth rates, allowing investors to determine if they are overpaying for future business expansion. The value 0.00 reflects the fundamental value of Geron Corporation (GERN), where monopoly pricing power for a unique myelodysplastic syndromes therapy should ensure a high growth rate, making the current PEG level a key indicator of the asset's undervaluation.

Competing companies

Nanobiotix SA (NBTX) - Price to Net Income Growth Ratio|Bicycle Pharma - Price/Earnings to Growth Multiple|CytomX Corp (CTMX) - Price to Earnings Adjusted for Growth Rate|CATX: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio GNLX (Genelux Corporation)|Molecular Partners (MOLN) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio ONCY (Oncolytics Biotech)|Price/Earnings to Growth Ratio Lisata Therapeutics Inc.|Price/Earnings to Growth Ratio MBRX|PEG Multiple GRTX|PEG Multiple mtem.com (MTEM)